| Patent Number |
Title Of Patent |
Date Issued |
| RE39862 |
Unsaturated 14, 15-cyclopropanoandrostanes, a method for their production and pharmaceutical com |
September 25, 2007 |
| The invention relates to new unsaturated 14,15-cyclopropano-androstanes of the general formula (I) ##STR00001## to their synthesis and to pharmaceutical compositions, containing these compounds.The compounds of formula (I) have gestagenic and/or androgenic activity. |
| 8193252 |
Mesoprogestins (progesterone receptor modulators) for the treatment and prevention of benign hor |
June 5, 2012 |
| This present invention disclosed the use of mesoprogestins, a new class of progesterone receptor modulators (PRMs), for the treatment and prevention of benign hormone dependent gynecological disorders: a) for the treatment of gynecological disorder such as endometriosis, uterine fibr |
| 7732493 |
2-substituted D-homo-estra-1,3,5(10)-trienes as inhibitors of 17.beta.-hydroxy steroid dehydroge |
June 8, 2010 |
| The invention relates to new 2-substituted D-homo-estra-1,3,5(10)-trienes of general formula I ##STR00001## in which R.sup.2 means a C.sub.1-C.sub.8-alkyl group, a C.sub.1-C.sub.8-alkyloxy group or a halogen atom, R.sup.13 means a hydrogen atom or a methyl group, R.sup.17 means a |
| 7629334 |
Mesoprogrestins (progesterone receptor modulations) as a component of compositions for hormone r |
December 8, 2009 |
| The use of mesoprogestins as pharmaceutical components for the manufacture of a medicament for hormone replacement therapy (HRT) and as components for the combined use together with an estrogen for the manufacture of a medicament for HRT as well as in respective HRT-methods and methods o |
| 7550451 |
Progesterone receptor modulators with increased antigonadotropic activity for female birth contr |
June 23, 2009 |
| The invention relates to new compounds of general formula I, ##STR00001## their production and pharmaceutical preparations that contain these compounds.The compounds according to the invention are preferably used for female birth control and for HRT. |
| 7534780 |
Estradiol prodrugs |
May 19, 2009 |
| The invention relates to estradiol prodrugs of general formula (I), in which group Z is bonded to the steroid, ##STR00001## process for their production, pharmaceutical compositions that contain these compounds, as well as their use for the production of pharmaceutical agents with e |
| 7507725 |
Compounds with sulphonamide group and pharmaceutical compositions containing these compounds |
March 24, 2009 |
| The invention relates to compounds which, acting as a prodrug and/or support, enable an active agent to be taken up by the erythrocytes and/or an active agent to bind to the erythrocytes. The uptake of these compounds by and/or the binding thereof to the erythrocytes is made possible |
| 7435757 |
2-substituted D-homo-estra-1,3,5(10)-trienes as inhibitors of 17.beta.-hydroxy steroid dehydroge |
October 14, 2008 |
| The invention relates to new 2-substituted D-homo-estra-1,3,5(10)-trienes of general formula I ##STR00001## in which R.sup.2 means a C.sub.1-C.sub.8-alkyl group, a C.sub.1-C.sub.8-alkyloxy group or a halogen atom, R.sup.13 means a hydrogen atom or a methyl group, R.sup.17 means a |
| 7419972 |
2-substituted estra-1,3,5(10)-trien-17-ones as inhibitors of 17.beta.-hydroxy steroid dehydrogen |
September 2, 2008 |
| The invention relates to new 2-substituted estra-1,3,5(10)-trien-17-ones of formula I ##STR00001## as well as their pharmaceutically acceptable salts, their methods of manufacture and use as medicaments for prophylaxis and/or therapy of estrogen-dependent diseases that can be influe |
| 7388003 |
.DELTA..sup.15-D-Homosteroids with androgenic action |
June 17, 2008 |
| The invention relates to .DELTA..sup.15-D-homosteroids of general formula (I) ##STR00001## process for their production and pharmaceutical compositions that contain these compounds.The compounds of general formula I according to the invention have androgenic activity. |
| 7378404 |
8.beta.-hydrocarbyl-substituted estratrienes for use as selective estrogens |
May 27, 2008 |
| This invention describes the new 8.beta.-substituted estratrienes of general formula I in which R.sup.2, R.sup.3, R.sup.6, R.sup.6', R.sup.7, R.sup.7', R.sup.9, R.sup.11, R.sup.11', R.sup.12, R.sup.14, R.sup.15, R.sup.15', R.sup.16, R.sup.16', R.sup.17 and R.sup.17' have the meanings |
| 7335650 |
Composition |
February 26, 2008 |
| There is provided a pharmaceutical composition comprising (i) a compound of the formula ##STR00001## wherein: X is a hydrocarbyl ring having at least 4 atoms in the ring; K is a hydrocarbyl group; Rs is a sulphamate group; (ii) optionally admixed with a pharmaceutically acceptable c |
| 7297702 |
Contraception method using competitive progesterone antagonists and novel compounds useful there |
November 20, 2007 |
| Competitive progesterone antagonists, including two novel steroids, viz., 11.beta.,19-[4-(cyanophenyl)-o-phenylene]-17.beta.-hydroxy-17.alpha.-(3-h- ydroxyprop-1(Z)-enyl)-4-androsten-3-one and 11.beta.,19-[4-(3-pyridinyl)-o-phenylene]-17.beta.-hydroxy-17.alpha.-(3-h- ydroxyprop-1(Z)-en |
| 7199115 |
17.alpha.-fluorosteroids, pharmaceutical compositions containing 17.alpha.-fluorosteroids and a |
April 3, 2007 |
| New 17.alpha.-fluorosteroid compounds of formula (I) are disclosed: ##STR00001## wherein R.sup.1 denotes H or methyl; R.sup.2 and R.sup.3 each denote H, Cl or methyl; and either a double bond or a single bond is present between C-6 and C-7 and also C-9 and C-10 of the steroid ring s |
| 7186728 |
Methylene-4-azasteroids |
March 6, 2007 |
| 17-methylene-4-azasteroid compounds of formula I: ##STR00001## wherein R.sup.20 denotes fluoro, chloro or bromo R.sup.20a denotes hydrogen, R.sup.10 and R.sup.4 each denote a hydrogen atom or a methyl group, and R.sup.1 and R.sup.2 each denote a hydrogen atom or together denote an a |
| 7053077 |
Use of biogenic estrogen sulfamates for hormone replacement therapy |
May 30, 2006 |
| The invention relates to the use of biogenic estrogen sulfamates for the oral discontinuous application for hormone replacement therapy (HRT). The discontinuous administration takes place in intervals ranging from 2 to 40 days. The invention also provides the additional application of |
| 6956031 |
11.beta.-Substituted 19-nor-17-.alpha.-pregna-1,3,5(10)-trien-17.beta.-ols with a 21,16.alpha.-l |
October 18, 2005 |
| This invention relates to new 19-nor-17.alpha.-pregna-1,3,5(10)-trien-17.beta.-ols with a 21,16.alpha.-lactone ring with a long-chain substituent in 11.beta.-position of general formula II ##STR1##in which R.sup.11 is a long-chain alkyl radical that has a nitrogen atom that can b |
| 6894038 |
Use of biogenic estriol diester prodrugs for the treatment of autoimmune diseases |
May 17, 2005 |
| The invention relates to the use of esters of estriol, for example, an estriol 3,17-dipropionate or an estriol 3,17-dihexanoate, for the treatment of autoimmune diseases, such as multiple sclerosis (MS). |
| 6855836 |
17-Methylene steroids, process for their production and pharmaceutical compositions that contain |
February 15, 2005 |
| The invention relates to 17-methylene steroids, process for their production and pharmaceutical compositions that contain these compounds.The compounds according to the invention have a hybrid-type profile of action in the sense that they act as inhibitors of 5.alpha.-reductase and simul |
| 6841548 |
Pharmaceutical preparations containing estra-1,3,5(10)-triene derivatives |
January 11, 2005 |
| The invention concerns pharmaceutical preparations containing estra-1,3,5(10)-triene derivatives as active ingredients which carry a group of the general formulaThe preparations according to the invention can be used for hormonal contraception and for hormon replacement therapy (HRT). Th |
| 6825182 |
17.alpha.-fluoroalkyl-11.beta.-benzaldoxime steroids, process for their production, pharmaceutic |
November 30, 2004 |
| Compounds of general formula I as well as their pharmaceutically compatible salts are described, in which R.sub.1 stands for hydrogen, C.sub.1 - to C.sub.6 -alkyl, COR.sub.4, COOR.sub.4, COSR.sub.4 or CONHR.sub.5, in which R.sub.4 is C.sub.1 - to C.sub.6 -alkyl or unsubstituted or substi |
| 6790853 |
Contraception method using competitive progesterone antagonists and novel compounds useful there |
September 14, 2004 |
| Competitive progesterone antagonists, including two novel steroids, viz., 11.beta.,19-[4-(cyanophenyl)-o-phenylene]-17.beta.-hydroxy-17.alpha.-(3-hy droxyprop-1(Z)-enyl)-4-androsten-3-one and 11.beta.,19-[4-(3-pyridinyl)-o-phenylene]-17.beta.-hydroxy-17.alpha.-(3-hy droxyprop-1(Z)-enyl |
| 6723715 |
14, 15-cyclopropanosteroids of the 19-norandrostane series, method for producing said compounds |
April 20, 2004 |
| The invention relates to the new 14,15-cyclopropanoandrosteroids of the 19-norandrostane series of the general formula (I) ##STR1##their synthesis and to pharmaceutical compositions containing these compounds.The compounds of formula (I) have an interesting, mixed androgen/gestagen p |
| 6710039 |
Unsaturated 14,15-cyclopropane-androstanes, a method for their production and pharamceutical com |
March 23, 2004 |
| The invention relates to new unsaturated 14,15-cyclopropano-androstanes of the general formula (I) ##STR1##to their synthesis and to pharmaceutical compositions, containing these compounds.The compounds of formula (I) have gestagenic and/or androgenic activity. |
| 6670347 |
19-nor-17.alpha.-pregna-1,3,5(10)-trien-17.beta.-ols with a 21,16.alpha.-lactone ring |
December 30, 2003 |
| This invention relates to new 19-nor-17.alpha.-pregna-1,3,5(10)-trien-17.beta.-ols with a 21,16.alpha.-lactone ring of formula II, ##STR1##process for their production and pharmaceutical preparations that contain these compounds as well as 17.alpha.-cyanomethylated estra-1,3,5(10 |
| 6653298 |
Composition |
November 25, 2003 |
| Disclosed and claimed are methods for oral contraception, or a hormone replacement therapy, or for treating breast cancer, in a patient in need thereof involving administering to the patient, at a dosage of no greater than 200 .mu.g/day per 70 kg subject, a compound having Formula (I): |
| 6608074 |
Contraception method using competitive progesterone antagonists and novel compounds useful there |
August 19, 2003 |
| Competitive progesterone antagonists, including two novel steroids, viz., 11.beta.,19-[4-(cyanophenyl)-o-phenylene]-17.beta.-hydroxy-17.alpha.-(3-hy droxyprop-1(Z)-enyl)-4-androsten-3-one and 11.beta.,19-[4-(3-pyridinyl)-o-phenylene]-17.beta.-hydroxy-17.alpha.-(3-hy droxyprop-1(Z)-enyl |
| 6583130 |
C13-substituted estra-1,3,5,(10)-trien-3-yl sulfamates, methods of preparing same, and pharmaceu |
June 24, 2003 |
| The invention relates to new C.sub.13 -substituted estra-1,3,5(10)-trien-3-yl sulfamates of general formula I, ##STR1##wherein R.sub.1 represents an acyl residue, oxycarbonyl residue, aminocarbonyl residue, sulfonyl residue, or aminosulfonyl residue, and R.sub.15 represents ethyl, me |
| 6569844 |
Pharmaceutical preparations containing estra-1,3,5(10)-triene derivatives |
May 27, 2003 |
| The invention concerns pharmaceutical preparations containing estra-1,3,5(10)-triene derivatives as active ingredients which carry a group of the general formulaat their C3 position wherein R is a R.sup.1 R.sup.2 N group wherein R.sup.1 and R.sup.2 are independent of each other and rep |
| 6534490 |
Unsaturated 14, 15-cyclopropanoandrostanes, method for the production thereof and pharmaceutical |
March 18, 2003 |
| Described are new, unsaturated 14,15-cyclopropano-androstanes of general formula (I) and their pharmaceutically acceptable salts, a process for their production and pharmaceutical preparations that contain these compounds. The compounds are characterized by hormonal (gestagenic and/or |
| 6436917 |
Non-estrogenic estradiol derivative compounds with anti-oxidative activity |
August 20, 2002 |
| New non-estrogenic derivative compounds of estradiol, which have no estrogenic activity and comparatively high anti-oxidative activity, are disclosed. These new non-estrogenic derivative compounds are potentially useful as non-estrogenic antioxidants, especially for administration in |
| 6388109 |
14,15-cyclopropano steroids of the 19-norandrostane series, method for the production thereof an |
May 14, 2002 |
| Described are new 14,15-cyclopropano steroids of the 19-norandrostane series of general formula (I) and their pharmaceutically acceptable salts, a process for their production and pharmaceutical preparations that contain these compounds. The compounds are distinguished by hormonal (g |
| 6365582 |
S-substitute 11.beta.-benzaldoxime-estra-4, 9-diene-carbonic acid thiolesters, method for the pr |
April 2, 2002 |
| Thiol esters of S-substituted 11.beta.-benzaldoxime-estra-4,9-dien-carboxylic acids of the formula I ##STR1##their pharmaceutically acceptable salts, a method for their synthesis and pharmaceutical preparations containing these compounds are described. These compounds bind to progest |
| 6340688 |
Contraception method using competitive progesterone antagonists and novel compounds useful there |
January 22, 2002 |
| Competitive progesterone antagonists, including two novel steroids, viz., 11.beta.,19-[4-(cyanophenyl)-o-phenylene]-17.beta.-hydroxy-17.alpha.-(3-hy droxyprop-1(Z)-enyl)-4-androsten-3-one and 11.beta.,19-[4-(3-pyridinyl)-o-phenylene]-17.beta.-hydroxy-17.alpha.-(3-hy droxyprop-1(Z)-enyl |
| 6225347 |
9-halogen-(Z)-prostaglandin derivatives, process for their production and their use as pharmaceu |
May 1, 2001 |
| The invention relates to 9-halogen-(Z) prostane derivatives of formula I ##STR1##in which ##STR2##Z represents the radicalsHal represents a chlorine or fluorine atom in the alpha or beta position,R.sub.1 represents the radical ##STR3##with R.sub.2 meaning a hydrogen atom, an alkyl, cyclo |
| 6080735 |
Estra-1,3,5(10)-trien derivatives, processes for their preparation and pharmaceutical compositio |
June 27, 2000 |
| This invention is relating to new estra-1,3,5(10)-trien-sulfamates carrying at the 3-position an R--SO.sub.2 --O--group, with R being an R.sup.1 R.sup.2 N--group in which R.sup.1 and R.sup.2, independently of each other, represent a hydrogen atom, an alkyl residue with 1-5 C atoms or, |
| 5891910 |
9-halogen-(Z) prostaglandin derivatives, process for their production and their use as pharmaceu |
April 6, 1999 |
| The invention relates to 9-halogen-(Z) prostane derivatives of formula I ##STR1## in which ##STR2## Z represents the radicals Hal represents a chlorine or fluorine atom,R.sub.1 represents ##STR3## A represents a --CH.sub.2 --CH.sub.2 --, a trans--CH=CH or --C.ident.C, W r |
| 5843933 |
11.beta.-aryl-4-estrenes, process for their production as well as their use as pharmaceutical ag |
December 1, 1998 |
| Compounds of formula I ##STR1## wherein X, R.sup.1, R.sup.2, R.sup.3 and R.sup.4 have the meanings indicated in the description, are described, as well as processes for their production, pharmaceutical preparations containing these compounds as well as their use for treatment of |
| 5843931 |
6,7-modified 11.beta.-aryl-4-oestrenes |
December 1, 1998 |
| Compounds of the general formula I ##STR1## are described, in which x represents an oxygen atom or the hydroxyimino grouping >N.about.OH,R.sup.1 represents a hydrogen atom or a methyl group,G represents a hydrogen atom, a halogen atom or a C.sub.1 -C.sub.4 -alkyl radical, when M a |
| 5795881 |
Combined use of an antigestagen and a progesterone synthesis inhibitor of the trilostane and epo |
August 18, 1998 |
| A pharmaceutical agent contains a progesterone synthesis inhibitor (ProI) of the trilostane or epostane type and an antigestagen (AG). It can be used for inducing delivery at term in humans and animals, for terminating normal or pathological pregnancies therein or for treatment of ho |
| 5744464 |
Antigestagens for the inhibition of uterine synthesis of prostaglandin |
April 28, 1998 |
| Antigestagens inhibit prostaglandin synthesis by the uterus and thus can be used to treat symptoms of dysmennhorea. |
| 5728689 |
11.beta.-aryl-4-estrenes, process for their production as well as their use as pharmaceutical ag |
March 17, 1998 |
| A method of inducing an antigestagenic effect by the administration of compounds of formula I: ##STR1## wherein, substituents are as defined in the specification. |
| 5705495 |
Sulfamate derivatives of 1,3,5(10)-estratriene derivatives, methods for their production and pha |
January 6, 1998 |
| The invention relates to new sulfamate derivatives of 1,3,5(10)-estratriene derivatives of the general formula I ##STR1## wherein the 3-sulfamate moiety is acylated, sulfonated or amidosulfonated. Furthermore, methods for the production of the compound and pharmaceutical preparat |
| 5693628 |
11-benzaldoxime-estra-diene derivatives, methods for their production and pharmaceuticals contai |
December 2, 1997 |
| This invention relates to new 11-benzaldoxime-estra-diene derivatives of the general formula I ##STR1## and their pharmaceutically acceptable salts, a method for their production, and pharmaceuticals containing such compounds.The compounds described show strong antigestagenic effects |
| 5614213 |
Use of estriol for treatment of climacteric osteoporosis |
March 25, 1997 |
| The invention relates to the use of estriol as the sole active ingredient for the production of a transdermal medicament which continuously releases the active ingredient for the treatment of climacteric osteoporosis. It has been shown according to the invention that estriol, which has u |
| 5576310 |
11-benzaldoxime-17.beta.-methoxy-17.alpha.-methoxymethyl-estrasdiene derivatives, methods for th |
November 19, 1996 |
| This invention relates to new 11-benzaldoxime-estra-diene derivatives of the general formula I ##STR1## wherein Z is --CO--CH.sub.3, --CO--O--C.sub.2 H.sub.5, --CO--NH-phenyl, --CO--NH--C.sub.2 H.sub.5, --CO--C.sub.2 H.sub.5, --CH.sub.3, or --CO-phenyland their pharmaceutically a |
| 5569652 |
Dihydrospirorenone as an antiandrogen |
October 29, 1996 |
| Dihydrospirorenone, ##STR1## preferably together with an estrogen, can be used for the production of a pharmaceutical agent suitable for treatment of hormonal irregularities during premenopause (menstruation stabilization), for hormonal substitution therapy during menopause, for |
| 5529993 |
14.alpha., 17.alpha.-ethano-16.alpha.-hydroxy-estratrienes |
June 25, 1996 |
| A 14.alpha.,17.alpha.-bridged estratriene of formula I ##STR1## wherein (a) OR.sup.3 is in .alpha.-positionR.sup.1, R.sup.2 and R.sup.3, each independently are (i) hydrogen, (ii) ##STR2## in which R.sup.4 is an organic radical with up to 11 carbon atoms or (iii) --(CH.sub.2).sub |
| 5519027 |
D-homo-(16-ene)-11.beta.-aryl-4-estrenes, process for their production as well as their use as p |
May 21, 1996 |
| New D-homo-(16-ene)-11.beta.-aryl-4-estrenes of general formula I ##STR1## as well as their pharmaceutically compatible addition salts with acids are described in whichX stands for an oxygen atom, the hydroxyimino grouping >N.about.OH or two hydrogen atoms,R.sup.1 stands for a hyd |
| 5491137 |
14.alpha.17.alpha.-(Propano-and 17.sup.2 propeno) -estratrienes |
February 13, 1996 |
| 14.alpha.,17.alpha.-(Propano-and 17.sup.2 -propeno)-estratrienes of general formula I ##STR1## in which R.sup.1 means a hydrogen atom, a methyl or an acyl group with 1-12 carbon atoms,R.sup.2 means a hydrogen atom or an acyl group with 1-12 carbon atoms and ##STR2## a C--C si |
